Q1 Earnings Forecast for ChromaDex Issued By HC Wainwright

ChromaDex Co. (NASDAQ:CDXC) – Research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of ChromaDex in a research report issued to clients and investors on Monday, March 10th. HC Wainwright analyst R. Selvaraju expects that the company will post earnings per share of $0.03 for the quarter. HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for ChromaDex’s current full-year earnings is $0.04 per share. HC Wainwright also issued estimates for ChromaDex’s Q2 2025 earnings at $0.04 EPS, Q3 2025 earnings at $0.04 EPS, Q4 2025 earnings at $0.06 EPS, FY2025 earnings at $0.17 EPS, Q1 2026 earnings at $0.05 EPS, Q2 2026 earnings at $0.06 EPS, Q3 2026 earnings at $0.08 EPS, Q4 2026 earnings at $0.11 EPS and FY2026 earnings at $0.29 EPS.

Several other equities analysts also recently weighed in on the company. StockNews.com downgraded ChromaDex from a “strong-buy” rating to a “buy” rating in a research report on Thursday, March 6th. LADENBURG THALM/SH SH raised their price objective on ChromaDex from $6.80 to $8.10 and gave the stock a “buy” rating in a report on Wednesday, March 5th.

ChromaDex Stock Performance

ChromaDex stock opened at $7.90 on Wednesday. The stock has a fifty day moving average of $5.87 and a two-hundred day moving average of $5.27. The company has a market capitalization of $614.23 million, a price-to-earnings ratio of 790.79 and a beta of 2.21. ChromaDex has a fifty-two week low of $1.77 and a fifty-two week high of $9.18.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Squarepoint Ops LLC acquired a new position in ChromaDex in the fourth quarter valued at $555,000. Two Sigma Investments LP acquired a new position in ChromaDex in the fourth quarter valued at $675,000. State of Wyoming acquired a new position in ChromaDex in the fourth quarter valued at $39,000. Sherbrooke Park Advisers LLC acquired a new position in ChromaDex in the fourth quarter valued at $94,000. Finally, ProShare Advisors LLC acquired a new position in ChromaDex in the fourth quarter valued at $74,000. Institutional investors and hedge funds own 15.41% of the company’s stock.

Insider Transactions at ChromaDex

In other news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the firm’s stock in a transaction on Friday, December 13th. The stock was sold at an average price of $6.19, for a total transaction of $230,026.59. Following the sale, the director now owns 244,179 shares in the company, valued at $1,511,468.01. This trade represents a 13.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 9.64% of the company’s stock.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.